Yeap Beaza is quite correct, it's a conservative estimate of what we could've reasonably received back then, I always had a Bil in mind but I went low ball.
Reminder...some 10 plus years ago...Tanenzumab was an anti inflammatory drug, circa efficacy of Zilosul...but ended up failing as it resulted in more RPOA (rapid progressive OA), rejected by FDA.
Yes correct, Tanenzumab was a NGF class drug...this means it blocks out Nerve Growth Factor totally.....
<warning warning> do this and you have an immunosuppressant on your hands...not good, get a mild case of bacterial infection and your body can't fight it... (iPPS downregulates NGF so the body can repair itself as it still receives the correct signals that initiates the repair processes!)
At the time it was thought that the market was worth some 11 Billion USD...at a P/e ratio of 20 thats a huge valuation for us...(My pal on the East coast says I should use a factor of 50).
Deal size? 1.8 Billion USD back then!
Yeah, no DMOAD
Guys, the pain market is quite simply enormous, Im hearing figs of around $49 Billion USD 2...
There are no great drugs that address pain effectively and of course, safely.
Ours does.
Our is safe...
REF:
1) https://www.fiercebiotech.com/partnering/eli-lilly-spells-out-1-8b-deal-to-partner-pfizer-on-tanezumab
2) https://www.thepharmaletter.com/article/pain-therapies-sales-to-exceed-49-billion-in-2026-driven-by-new-product-launches
PAR. SP, page-907
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
0.005(2.08%) |
Mkt cap ! $85.73M | |||
| Open | High | Low | Value | Volume |
| 24.0¢ | 25.0¢ | 23.0¢ | $180.4K | 746.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 79748 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 22818 | 4 |
View Market Depth
| Last trade - 16.10pm 14/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |